Merck & Co., Inc. (NYSE:MRK) Posts Quarterly Earnings Results

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13, FiscalAI reports. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. updated its FY 2026 guidance to 2.660-2.760 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck raised and narrowed its 2026 revenue outlook to $66.3 billion–$67.3 billion, while maintaining confidence in continued growth driven by oncology, animal health, and newer product launches.
• New and expanding products showed strong momentum, including WINREVAIR sales up 75%, WELIREG sales up 67%, and CAPVAXIVE sales up 40%; LIPFENDRA also received FDA approval as the first oral PCSK9 inhibitor.
• Pipeline de-risking accelerated, with positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis, while weekly oral HIV-treatment data and multiple upcoming regulatory milestones support Merck’s projected long-term growth opportunities.
• Second-quarter reported EPS was a loss of $0.13, including a $2.31-per-share one-time charge tied to the Terns acquisition; Merck also expects U.S. KEYTRUDA growth to moderate, an OHTUVAYRE sales unwind in the third quarter, and higher inventory reserves to pressure margins.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded up $0.54 during trading hours on Tuesday, reaching $128.31. 3,403,931 shares of the stock traded hands, compared to its average volume of 10,762,633. The company has a market capitalization of $316.91 billion, a P/E ratio of 36.14, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19. The company’s 50-day simple moving average is $123.28 and its two-hundred day simple moving average is $118.66. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Institutional Trading of Merck & Co., Inc.

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its stake in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares in the last quarter. Quattro Advisors LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth approximately $54,000. Alvarez & Marsal Private Wealth Partners LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at $47,000. Finally, Sfam LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $68,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MRK has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. CICC Research initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target on the stock. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, Barclays raised their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. The company also posted a narrower-than-expected loss of $0.13 per share, compared with the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, while the newer injectable formulation reportedly generated more than $200 million above Wall Street’s forecast. Strength in oncology and other newer products helped Merck raise its full-year revenue guidance to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion consensus. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Neutral Sentiment: Management highlighted regulatory approvals, clinical progress and a broad development pipeline, which could support longer-term growth as Merck works to diversify beyond Keytruda. Merck announces second-quarter 2026 financial results and pipeline milestones
• Negative Sentiment: Merck cut its fiscal 2026 adjusted EPS guidance to $2.66-$2.76, well below the $3.42 analyst consensus. The reduction reflects acquisition-related charges, particularly costs tied to the purchase of Terns Pharmaceuticals, and overshadows the quarterly earnings beat. Merck hikes revenue outlook but cuts profit guidance due to deal charges
• Negative Sentiment: The quarterly loss compares with earnings of $2.13 per share in the year-ago period, underscoring the near-term impact of acquisition and investment costs on profitability. Merck reports second-quarter loss and beats revenue estimates

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.